Retinoblastoma regression following intra-arterial chemotherapy to the contralateral eye

Intra-arterial chemotherapy (IAC) has assumed a major role in the management of retinoblastoma. This targeted therapy involves the delivery of chemotherapy directly into the ophthalmic artery, minimizing systemic absorption. We report a case of retinoblastoma regression in the untreated eye followin...

Descripción completa

Detalles Bibliográficos
Autores principales: Su, Grace L., Lim, Li-Anne S., Welch, R. Joel, Shields, Carol L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6819715/
https://www.ncbi.nlm.nih.gov/pubmed/31686972
http://dx.doi.org/10.1016/j.sjopt.2019.05.007
_version_ 1783463798686875648
author Su, Grace L.
Lim, Li-Anne S.
Welch, R. Joel
Shields, Carol L.
author_facet Su, Grace L.
Lim, Li-Anne S.
Welch, R. Joel
Shields, Carol L.
author_sort Su, Grace L.
collection PubMed
description Intra-arterial chemotherapy (IAC) has assumed a major role in the management of retinoblastoma. This targeted therapy involves the delivery of chemotherapy directly into the ophthalmic artery, minimizing systemic absorption. We report a case of retinoblastoma regression in the untreated eye following IAC to the contralateral eye.
format Online
Article
Text
id pubmed-6819715
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-68197152019-11-04 Retinoblastoma regression following intra-arterial chemotherapy to the contralateral eye Su, Grace L. Lim, Li-Anne S. Welch, R. Joel Shields, Carol L. Saudi J Ophthalmol Article Intra-arterial chemotherapy (IAC) has assumed a major role in the management of retinoblastoma. This targeted therapy involves the delivery of chemotherapy directly into the ophthalmic artery, minimizing systemic absorption. We report a case of retinoblastoma regression in the untreated eye following IAC to the contralateral eye. Elsevier 2019 2019-07-16 /pmc/articles/PMC6819715/ /pubmed/31686972 http://dx.doi.org/10.1016/j.sjopt.2019.05.007 Text en © 2019 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Su, Grace L.
Lim, Li-Anne S.
Welch, R. Joel
Shields, Carol L.
Retinoblastoma regression following intra-arterial chemotherapy to the contralateral eye
title Retinoblastoma regression following intra-arterial chemotherapy to the contralateral eye
title_full Retinoblastoma regression following intra-arterial chemotherapy to the contralateral eye
title_fullStr Retinoblastoma regression following intra-arterial chemotherapy to the contralateral eye
title_full_unstemmed Retinoblastoma regression following intra-arterial chemotherapy to the contralateral eye
title_short Retinoblastoma regression following intra-arterial chemotherapy to the contralateral eye
title_sort retinoblastoma regression following intra-arterial chemotherapy to the contralateral eye
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6819715/
https://www.ncbi.nlm.nih.gov/pubmed/31686972
http://dx.doi.org/10.1016/j.sjopt.2019.05.007
work_keys_str_mv AT sugracel retinoblastomaregressionfollowingintraarterialchemotherapytothecontralateraleye
AT limliannes retinoblastomaregressionfollowingintraarterialchemotherapytothecontralateraleye
AT welchrjoel retinoblastomaregressionfollowingintraarterialchemotherapytothecontralateraleye
AT shieldscaroll retinoblastomaregressionfollowingintraarterialchemotherapytothecontralateraleye

Ejemplares similares